Navigation Links
Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
Date:6/26/2008

Quark's second siRNA drug delivered systemically

FREMONT, Calif., June 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its siRNA drug candidate, DGFi, in kidney transplantation. The Company expects its Phase I/II clinical study for prevention/treatment of Delayed Graft Function (DGF) in kidney transplant patients to begin in the second half of 2008.

DGFi is Quark's second product candidate to enter clinic trials that is systemically administered to patients. The first ever siRNA drug candidate to be delivered systemically in man was Quark's AKIi-5 which is in Phase I clinical trial for acute kidney injury.

The Phase I/II will be a multi center study in which the safety and tolerability of escalating doses of DGFi by a single IV injection in renal transplant patients with DGF. Up to 204 adult kidney transplant recipients will be enrolled in this 2-part study.

"We are pleased with the FDA acceptance of our DGFi IND application for prevention of delayed graft function, which is a very serious medical issue for kidney transplant patients," said Shai Erlich, Ph.D., Chief Development Officer of Quark. "This is an important milestone for us. It marks Quark's third clinical program and the second in which our siRNA drug is administered systemically to patients. This achievement provides further validation of Quark's RNAi based drug discovery approach."

About DGF and Kidney Transplant

Delayed Graft Function (DGF) in renal transplantation is a syndrome caused by ischemia and reperfusion injury. Ischemia reperfusion injury occurs frequently in kidneys that have been outside a living human body and damaged from lack of oxygen in the kidneys that have been blood deprived. In patients with DGF the transplanted kidney does not function properly and requires intervention by dialysis.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Grieving children from northern Allegheny, Armstrong, Beaver, Butler, ... to be served at new facility, PITTSBURGH, Feb. ... Children, Adolescents and Their Families, announced today its,intention to ... Cranberry,area, which will aim to serve children and families ...
... For years, getting a lot of,calcium has been ... do to,prevent osteoporosis and related bone fractures. Small study ... the data from,large, prospective studies that followed people for ... 2008 issue of the Harvard,Health Letter., The ambiguity ...
... Americans who,are unaware they have diabetes or are at ... Risk Test, ALEXANDRIA, Va., Feb. 25 The ... WHAT: The American Diabetes Association will "sound the alert" ... Tuesday, March 25,2008. American Diabetes Alert Day is a ...
... reducing cross contaminations including Influenza and ... ... today introduced,the new SILVER SEAL(TM) Washable, Antimicrobial Mouse at the HiMSS,Healthcare Symposium ... world,s first computer mouse to be fully submersible,dishwasher safe, and manufactured from ...
... With Standardized Pomegranate Extract and Pomegranate Seed Oil ... and Cell Protecting Benefits, EL SEGUNDO, Calif., ... use of,pomegranate in skincare for anti-inflammatory, antioxidant and ... equal; it is,the quality of the extract that ...
... AS PART OF ... SMART HEART CHALLENGE CAMPAIGN, CHICAGO, Feb. 25 Quaker ... hearts. Thanks to thousands of,Americans who signed up to take the ... King Cardiac Foundation (LKCF).,As part of this heart healthy campaign to ...
Cached Medicine News:Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 2Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 3Health News:High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter 2Health News:Sound the Alert!!! - March 25 is the 20th Annual American Diabetes Alert(R) Day 2Health News:Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 3Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 2Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 3
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 26, 2011 Revenue of $374 million grew 5 ... share were $0.55 compared to $0.31 in the prior year, an increase of ... points to 13.3 percent Fiscal year 2011 ... 7 percent and earnings are expected to be $2.18 to $2.26 per diluted ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported ... 31, 2010. The Company reported total revenue of $174.2 ... net product sales of $162.3 million and revenue under ... $22.9 million for the quarter ended December 31, 2010, ...
Cached Medicine Technology:Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 2Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 3Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 4Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 5Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 6Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 7Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 8Amylin Pharmaceuticals Reports 2010 Financial Results 2Amylin Pharmaceuticals Reports 2010 Financial Results 3Amylin Pharmaceuticals Reports 2010 Financial Results 4Amylin Pharmaceuticals Reports 2010 Financial Results 5Amylin Pharmaceuticals Reports 2010 Financial Results 6Amylin Pharmaceuticals Reports 2010 Financial Results 7Amylin Pharmaceuticals Reports 2010 Financial Results 8Amylin Pharmaceuticals Reports 2010 Financial Results 9
... firm support and stabilization for non-operable hip ... total hip arthroplasty. Neoprene padding is secured ... wicking interface. This brace may be ordered ... Genesis joints. , ,POSTERIOR PANEL: ...
... Philippon Post-Op Hip Brace was developed in ... of Sports Medicine/Hip Disorders at the University ... as well as abduction and adduction in ... brace can also lock in any position ...
... The B3 Triplanar hip ... planes; Flexion - extension, abduction ... standard on our Boston Post-Op ... on our custom Hip Spicas ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: